Mitochondrial Nucleotide Carriers of NRTI Metabolites
NRTI 代谢物的线粒体核苷酸载体
基本信息
- 批准号:7275281
- 负责人:
- 金额:$ 36.91万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-09-30 至 2009-08-31
- 项目状态:已结题
- 来源:
- 关键词:ATP phosphohydrolaseAcquired Immunodeficiency SyndromeAddressAdenineAdenine NucleotidesAdverse effectsAffinityAmino AcidsAntiviral AgentsBiochemical GeneticsBiological AssayCarboxylic AcidsCardiacCardiomyopathiesCarnitineCarrier ProteinsCatalogingCatalogsCell LineCharacteristicsChronicCitrateCitratesClinicalCoenzyme AComplementDNA MaintenanceDNA biosynthesisDNA chemical synthesisDNA-Directed DNA PolymeraseDeoxyribonucleotidesDevelopmental Therapeutics ProgramDiphosphatesDisruptionElectron TransportElectronsEquilibriumEukaryotaEukaryotic CellExclusionFailureFamilyFamily memberFatty AcidsFishesFlavin MononucleotideFolateGenerationsGenesGeneticGlutamineGoalsHIVHeartHereditary DiseaseHumanIn VitroKineticsLGLALactic AcidosisLightLiposomesMaintenanceMalatesMammalian CellMeasuresMediatingMembraneMetabolismMethionineMitochondriaMitochondrial DNAMitochondrial ProteinsMusMuscle FibersMyopathyNeuropathyNicotinamide adenine dinucleotideNucleoside TransporterNucleosidesNucleotidesNumbersOligopeptidesOrnithineOrphanOrthologous GeneParentsPathway interactionsPatientsPeripheral Nervous System DiseasesPharmaceutical PreparationsPhenotypePhysiologicalPlantsPlayPolymerase Chain ReactionPost-Translational Protein ProcessingPrincipal InvestigatorProdrugsProductionProtein BiosynthesisProtein OverexpressionProteinsProteolysisProtonsRNA InterferenceRNA-Directed DNA PolymeraseRadioRateResistanceRespiratory FailureRespiratory physiologyRetroviridaeReverse Transcriptase InhibitorsRodentRoleSaccharomyces cerevisiaeStructureSymptomsSystemTestingTherapeutic IndexTimeTissuesToxic effectTransgenesViralViral PhysiologyYeastsZalcitabineZidovudineanalogchemical groupcofactorcytochrome cflyhuman prostaglandin D2 receptorhydroxyl groupimprovedin vivoindexingmalatemanmembermitochondrial dysfunctionmitochondrial genomemutantnovelnucleoside analogoxidationprogramsproteoliposomesradiochemicalreconstitutionrespiratoryresponsesmall moleculesugarsynthetic nucleic acidtripolyphosphateuptakezidovudine triphosphate
项目摘要
DESCRIPTION (provided by applicant):
Nucleoside reverse transcriptase inhibitors (NRTI) are critical components of highly active anti-viral therapies. Phosphorylated derivatives (NRTI-P) mimic the cellular dNTP substrates for HIV RT, but produce chain termination, thereby limiting retroviral amplification. NRTIs produce reversible side effects that resemble those of patients with mitochondrial (mito) genetic disorders, including cardiomyopathy, myopathy, neuropathy and lactic acidosis, and these correlate with NRTI-induced loss of mito DNA in various tissues. Toxicity has been attributed to inhibition of DNA polymerase g, interfering with mito DNA maintenance. Alternative or additional mechanisms of mito damage may also be at play. Regardless of mechanism, NRTI toxicity is dependent on import into mito. We have isolated novel human genes and cDNAs that encode orphan members of the mito metabolite carrier family (OMC). Five carry a signature specific to nucleotide (nt) carriers, including a putative adenine nt transporter (ANT), two putative CoA transporters, and a non-specific exchanger of nucleotides (OMC27). We have shown that purified OMC27 and its yeast ortholog transport NRTI-P's AZT-TP and -DP, ddl-TP, and ddC-TP in proteoliposome radiochemical flux assays. Disruption of the orthologous yeast gene protects against AZT-induced mito dysfunction. This project examines the role of OMC27 in NRTI-mediated toxicity, with goals of understanding mechanisms by which NRTIs gain entry to the matrix, and identifying nucleoside analogs with known anti-viral activity that offer potential for improved therapeutic index by virture of mito exclusion and reduced mito toxicity. We will test the hypotheses that OMC27 (and yeast ortholog) are highly affinity transporters of NRTI-P, that this represents the primary pathway for mito uptake of NRTI-P; that OMC27 expression is critical to NRTI-induced mito failure; and that a useful therapeutic index for NRTIs may be evident from the ratio of NRTI anti-viral to MC-mediated uptake activities; using complementary in vitro, yeast and mammalian cell, and in vivo mouse studies.
描述(由申请人提供):
核苷逆转录酶抑制剂(NRTI)是高活性抗病毒疗法的关键成分。 磷酸化衍生物(NRTI-P)模仿HIV RT的细胞DNTP底物,但会产生链终止,从而限制了逆转录病毒扩增。 NRTI产生可逆的副作用,类似于线粒体(MITO)遗传疾病的患者,包括心肌病,肌病,肌病,神经病和乳酸酸中毒,这些副作用与NRTI-I诱导的各种组织中的MITO DNA丧失相关。 毒性归因于DNA聚合酶G的抑制,并干扰了MITO DNA维持。 MITO损坏的替代或其他机制也可能正在发挥作用。 不管机制如何,NRTI毒性取决于进口到MITO。 我们拥有孤立的新型人类基因和cDNA,它们编码了Mito代谢物载体家族(OMC)的孤儿成员。 五个携带特异性的核苷酸(NT)载体的特定特征,包括推定的腺嘌呤NT转运蛋白(ANT),两个推定的COA转运蛋白和一个非特异性核苷酸交换器(OMC27)。 我们已经表明,在蛋白质体放射化学通量测定中,纯化的OMC27及其酵母直系基因运输NRTI-P的AZT-TP和-DP,DDL-TP和DDC-TP。 直系同源酵母基因的破坏可预防AZT诱导的MITO功能障碍。 该项目研究了OMC27在NRTI介导的毒性中的作用,其目标是理解NRTIS通过该毒性进入基质的机制,并鉴定具有已知抗病毒活性的核苷类似物,这些核苷类似物具有通过MITO排除和减少MITO MITO毒性来改善治疗指数的潜力。 我们将测试OMC27(和酵母直系同源物)是NRTI-P的高亲和力转运蛋白,这是MITO摄取NRTI-P的主要途径; OMC27的表达对于NRTI诱导的线粒体衰竭至关重要。 NRTI抗病毒与MC介导的摄取活动的比率可以明显看出NRTI的有用的治疗指数;使用互补的体外,酵母和哺乳动物细胞以及体内小鼠研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TOD GULICK其他文献
TOD GULICK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TOD GULICK', 18)}}的其他基金
An interdisciplinary approach to elucidate mechanisms of muscle lipotoxicity
阐明肌肉脂毒性机制的跨学科方法
- 批准号:
8184449 - 财政年份:2011
- 资助金额:
$ 36.91万 - 项目类别:
Mitochondrial Nucleotide Carriers of NRTI Metabolites
NRTI 代谢物的线粒体核苷酸载体
- 批准号:
6804111 - 财政年份:2003
- 资助金额:
$ 36.91万 - 项目类别:
Mitochondrial Nucleotide Carriers of NRTI Metabolites
NRTI 代谢物的线粒体核苷酸载体
- 批准号:
6936621 - 财政年份:2003
- 资助金额:
$ 36.91万 - 项目类别:
Mitochondrial Nucleotide Carriers of NRTI Metabolites
NRTI 代谢物的线粒体核苷酸载体
- 批准号:
7115805 - 财政年份:2003
- 资助金额:
$ 36.91万 - 项目类别:
Mitochondrial Nucleotide Carriers of NRTI Metabolites
NRTI 代谢物的线粒体核苷酸载体
- 批准号:
6709662 - 财政年份:2003
- 资助金额:
$ 36.91万 - 项目类别:
CARNITINE PALMITOYLTRANSFERASE I ISOFORM FUNCTION
肉碱棕榈酰转移酶 I 同工酶功能
- 批准号:
6292950 - 财政年份:2001
- 资助金额:
$ 36.91万 - 项目类别:
CARNITINE PALMITOYLTRANSFERASE I ISOFORM FUNCTION
肉碱棕榈酰转移酶 I 同工酶功能
- 批准号:
6868938 - 财政年份:2001
- 资助金额:
$ 36.91万 - 项目类别:
CARNITINE PALMITOYLTRANSFERASE I ISOFORM FUNCTION
肉碱棕榈酰转移酶 I 同工酶功能
- 批准号:
6626980 - 财政年份:2001
- 资助金额:
$ 36.91万 - 项目类别:
CARNITINE PALMITOYLTRANSFERASE I ISOFORM FUNCTION
肉碱棕榈酰转移酶 I 同工酶功能
- 批准号:
6701817 - 财政年份:2001
- 资助金额:
$ 36.91万 - 项目类别:
CARNITINE PALMITOYLTRANSFERASE I ISOFORM FUNCTION
肉碱棕榈酰转移酶 I 同工酶功能
- 批准号:
6489732 - 财政年份:2001
- 资助金额:
$ 36.91万 - 项目类别:
相似海外基金
MOLECULAR MECHANISMS OF V-ATPASES: ASSEMBLY, BIOGENESIS, REGULATION, AND FUNCTION
V-ATP酶的分子机制:组装、生物发生、调节和功能
- 批准号:
10501202 - 财政年份:2022
- 资助金额:
$ 36.91万 - 项目类别:
Molecular Mechanisms Of V-ATPases: Assembly,Biogenesis, Regulation, And Function
V-ATP 酶的分子机制:组装、生物发生、调节和功能
- 批准号:
10798892 - 财政年份:2022
- 资助金额:
$ 36.91万 - 项目类别:
MOLECULAR MECHANISMS OF V-ATPASES: ASSEMBLY, BIOGENESIS, REGULATION, AND FUNCTION
V-ATP酶的分子机制:组装、生物发生、调节和功能
- 批准号:
10664015 - 财政年份:2022
- 资助金额:
$ 36.91万 - 项目类别:
NANOSCALE ARCHITECTURE OF ESCRT MACHINERY IN HIV RELEASE
HIV 释放中 ESCRT 机器的纳米级架构
- 批准号:
8993494 - 财政年份:2015
- 资助金额:
$ 36.91万 - 项目类别:
Interactive Effects of Cannabinoids and Sex Hormones in Females
大麻素和性激素对女性的相互作用
- 批准号:
8827986 - 财政年份:2015
- 资助金额:
$ 36.91万 - 项目类别: